Luca Pani

University of Padua

Papers

1

Total Citations

6

H-Index

1

About

Dr. Luca Pani is a leading figure in clinical psychopharmacology and regulatory neuroscience, whose work bridges the gap between novel therapeutics and real-world patient outcomes. His research centers on the neurobiology of mood disorders, dissociative symptoms, and the development of rapid-acting antidepressants. A major contribution is his pioneering investigation into REL-1017 (Esmethadone), demonstrating its potential to rapidly reduce dissociative symptoms in adults with major depressive disorder unresponsive to standard treatments. This work addresses a critical, underdiagnosed comorbidity, as highlighted in his 2022 paper (6 citations), which notes that while 29% of psychiatric outpatients experience dissociative disorders, only 5% had previously been diagnosed. Dr. Pani’s impact extends beyond academia; he has served as a key opinion leader in regulatory science, shaping how novel compounds are evaluated for safety and efficacy. His contributions are vital for students and researchers interested in the intersection of pharmacology, psychiatry, and regulatory innovation, offering a pathway toward more personalized and effective treatments for treatment-resistant depression.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants
6 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: University of Padua

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 15 days ago